POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies.
The evolutionarily conserved human polymerase delta (POLD1) gene encodes the large p125 subunit which provides the essential catalytic activities of polymerase δ (Polδ), mediated by 5'-3' DNA polymerase and 3'-5' exonuclease moieties. POLD1 associates with three smaller subunits (POLD2, POLD3, POLD4), which together with Replication Factor C and Proliferating Nuclear Cell Antigen constitute the polymerase holoenzyme. Polδ function is essential for replication, with a primary role as the replicase for the lagging strand. Polδ also has an important proofreading ability conferred by the exonuclease activity, which is critical for ensuring replicative fidelity, but also serves to repair DNA lesions arising as a result of exposure to mutagens. Polδ has been shown to be important for multiple forms of DNA repair, including nucleotide excision repair, double strand break repair, base excision repair, and mismatch repair. A growing number of studies in the past decade have linked germline and sporadic mutations in POLD1 and the other subunits of Polδ with human pathologies. Mutations in Polδ in mice and humans lead to genomic instability, mutator phenotype and tumorigenesis. The advent of genome sequencing techniques has identified damaging mutations in the proofreading domain of POLD1 as the underlying cause of some inherited cancers, and suggested that mutations in POLD1 may influence therapeutic management. In addition, mutations in POLD1 have been identified in the developmental disorders of mandibular hypoplasia, deafness, progeroid features and lipodystrophy and atypical Werner syndrome, while changes in expression or activity of POLD1 have been linked to senescence and aging. Intriguingly, some recent evidence suggests that POLD1 function may also be altered in diabetes. We provide an overview of critical Polδ activities in the context of these pathologic conditions.
Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Emmanuelle
E
Nicolas
Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Erica A
EA
Golemis
Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. Electronic address: sanjeevani.arora@fccc.edu.
Sanjeevani
S
Arora
D000375:Aging / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000818:Animals; D063646:Carcinogenesis / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D004258:DNA Polymerase III / Q000235:genetics* / Q000378:metabolism; D004260:DNA Repair; D004261:DNA Replication; D005786:Gene Expression Regulation; D006801:Humans; D051379:Mice; D009154:Mutation; D009369:Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D018809:Proliferating Cell Nuclear Antigen / Q000235:genetics / Q000378:metabolism; D021122:Protein Subunits / Q000235:genetics* / Q000378:metabolism; D051818:Replication Protein C / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D014898:Werner Syndrome / Q000235:genetics / Q000378:metabolism / Q000473:pathology
D018809:Proliferating Cell Nuclear Antigen; D021122:Protein Subunits; C434055:POLD1 protein, human; D004258:DNA Polymerase III; D051818:Replication Protein C
DNA damage response; Hypermutation; MDPL syndrome; POLD1; Polymerase delta; Replication; p125